# US 10,501,463 B2 · Antibacterial cyclopenta[C]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,501,463 B2
- Document ID: US10501463B2
- Status: Granted
- Kind: B2
- Application number: 16/194,052
- Filed: 2018-11-16
- Published: 2019-03-21
- Granted: 2019-12-10
- Earliest claimed: 2011-08-10
- Assignees: Janssen Sciences Ireland Unlimited Company
- Applicants: Janssen Sciences Ireland Unlimited Company
- Inventors: Jerôme Emile Georges Guillemont; David Francis Alain Lançois; Magali Madeleine Simone Motte; Anil Koul; Wendy Mia Albert Balemans; Eric Pierre Alexandre Arnoult
- Web page: https://patentgrep.com/patent/US10501463B2

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 31/04: Antibacterial agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 487/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is related to novel compounds of formula (I) that inhibit the activity of the FabI enzyme which are therefore useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.

## Claims

### Claim 1

Compound
or a pharmaceutically acceptable salt thereof.

### Claim 2

Compound
or a pharmaceutically acceptable salt thereof.

### Claim 3

Compound
or a pharmaceutically acceptable salt thereof.